Table 4.
Women | Men | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
DI quintile | successfully-invited population | no. of participants | % participation | OR | (95 % CI) | DI quintile | successfully-invited population | no. of participants | % participation | OR | (95 % CI) |
I (least disadvantaged) | 26193 | 17228 | 65.73 | 1.00 | I (least disadvantaged) | 23947 | 14743 | 61.87 | 1.00 | ||
II | 24373 | 17026 | 69.89 | 1.21 | (1.16-1.25) | II | 23373 | 15079 | 64.91 | 1.14 | (1.10-1.19) |
III | 22632 | 16160 | 71.46 | 1.30 | (1.25-1.35) | III | 21440 | 14086 | 66.07 | 1.20 | (1.15-1.25) |
IV | 19927 | 13819 | 69.30 | 1.17 | (1.13-1.22) | IV | 19343 | 12349 | 64.07 | 1.10 | (1.06-1.14) |
V (most disadvantaged) | 19409 | 12820 | 66.06 | 1.01 | (0.97-1.05) | V (most disadvantaged) | 18483 | 11069 | 60.25 | 0.93 | (0.90-0.97) |
p < 0.001 | p < 0.001 | ||||||||||
DI quintile | no. of participants | no. of lesions (premal. + malignant) | rate of lesions (premal. + malignant) among participantsa | OR | (95 % CI) | DI quintile | no. of participants | no. of lesions (premal. + malignant) | rate of lesions (premal. + malignant) among participants | OR | (95 % CI) |
I (least disadvantaged) | 17228 | 255 | 15.39 | 1.00 | I (least disadvantaged) | 14743 | 594 | 40.99 | 1.00 | ||
II | 17026 | 246 | 14.61 | 0.97 | (0.81-1.16) | II | 15079 | 705 | 48.73 | 1.18 | (1.06-1.32) |
III | 16160 | 258 | 16.12 | 1.07 | (0.90-1.27) | III | 14086 | 703 | 50.76 | 1.25 | (1.12-1.40) |
IV | 13819 | 233 | 16.99 | 1.11 | (0.93-1.33) | IV | 12349 | 617 | 49.83 | 1.23 | (1.10-1.38) |
V (most disadvantaged) | 12820 | 197 | 15.40 | 1.01 | (0.84-1.22) | V (most disadvantaged) | 11069 | 608 | 55.68 | 1.38 | (1.23-1.55) |
p = 0.600 | p = 0.002 | RII 1.37 (1.21-1-55) | |||||||||
DI quintile | no. of participants | no. of malignant lesions | rate of malignant lesions among participantsa | OR | (95 % CI) | DI quintile | no. of participants | no. of malignant lesions | rate of malignant lesions among participants | OR | (95 % CI) |
I (least disadvantaged) | 17228 | 38 | 2,25 | 1,00 | I (least disadvantaged) | 14743 | 78 | 5,46 | 1,00 | ||
II | 17026 | 37 | 2,24 | 0,98 | (0.62-1.54) | II | 15079 | 85 | 6,14 | 1,08 | (0.80-1.48) |
III | 16160 | 38 | 2,37 | 1,05 | (0.67-1.65) | III | 14086 | 93 | 6,89 | 1,25 | (0.92-1.69) |
IV | 13819 | 31 | 2,35 | 0,97 | (0.60-1.56) | IV | 12349 | 45 | 3,60 | 0,66 | (0.45-0.95) |
V (most disadvantaged) | 12820 | 37 | 2,90 | 1,25 | (0.79-1.97) | V (most disadvantaged) | 11069 | 68 | 6,37 | 1,14 | (0.82-1.58) |
p = 0.824 | p = 0.006 | ||||||||||
DI quintile | no. of participants | no. of carcinomas stage III/IV | no. of carcinomas stage III/IV | OR | (95 % CI) | DI quintile | no. of participants | no. of carcinomas stage III/IV | no. of carcinomas stage III/IV | OR | (95 % CI) |
I (least disadvantaged) | 17228 | 10 | 0.70 | 1.00 | I (least disadvantaged) | 14743 | 24 | 1.97 | 1.00 | ||
II | 17026 | 14 | 0.84 | 1.27 | (0.59-2.76) | II | 15079 | 27 | 2.03 | 1.00 | (0.59-1.69) |
III | 16160 | 10 | 0.67 | 0.97 | (0.42-2.22) | III | 14086 | 20 | 1.52 | 0.75 | (0.41-1.32) |
IV | 13819 | 12 | 0.89 | 1.23 | (0.54-2.76) | IV | 12349 | 12 | 0.94 | 0.49 | (0.24-0.93) |
V (most disadvantaged) | 12820 | 13 | 0.99 | 1.44 | (0.65-3.20) | V (most disadvantaged) | 11069 | 22 | 2.13 | 1.02 | (0.58-1.77) |
p = 0.853 | p = 0.137 | ||||||||||
DI quintile | people with + FOBT | people who had colonoscopy | % colonoscopies | OR | (95 % CI) | DI quintile | people with + FOBT | people who had colonoscopy | % colonoscopies | OR | (95 % CI) |
I (least disadvantaged) | 773 | 688 | 89.07 | 1.00 | I (least disadvantaged) | 1168 | 1056 | 90.51 | 1.00 | ||
II | 789 | 723 | 91.64 | 1.34 | (0.96-1.89) | II | 1295 | 1205 | 92.96 | 1.41 | (1.06-1.89) |
III | 735 | 685 | 93.45 | 1.68 | (1.17-2.44) | III | 1292 | 1227 | 94.89 | 2.01 | (1.47-2.77) |
IV | 688 | 647 | 93.99 | 1.94 | (1.32-2.88) | IV | 1154 | 1102 | 95.60 | 2.25 | (1.61-3.18) |
V (most disadvantaged) | 665 | 622 | 93.65 | 1.78 | (1.22-2.63) | V (most disadvantaged) | 1119 | 1037 | 92.51 | 1.33 | (0.99-1.80) |
p = 0.003 | p = <0.001 | ||||||||||
DI quintile | people who had colonoscopy | no. of lesions (premal. + malignant) | % lesions found in colonoscopy | OR | (95 % CI) | DI quintile | people who had colonoscopy | no. of lesions (premal. + malignant) | % lesions found in colonoscopy | OR | (95 % CI) |
I (least disadvantaged) | 688 | 255 | 37.01 | 1.00 | I (least disadvantaged) | 1056 | 594 | 55.46 | 1.00 | ||
II | 723 | 246 | 33.88 | 0.88 | (0.70-1.09) | II | 1205 | 705 | 57.23 | 1.10 | (0.93-1.30) |
III | 685 | 258 | 37.72 | 1.03 | (0.82-1.27) | III | 1227 | 703 | 56.27 | 1.05 | (0.88-1.24) |
IV | 647 | 233 | 36.14 | 0.95 | (0.76-1.19) | IV | 1102 | 617 | 54.97 | 0.99 | (0.83-1.17) |
V (most disadvantaged) | 622 | 197 | 31.01 | 0.79 | (0.63-0.99) | V (most disadvantaged) | 1037 | 608 | 57.61 | 1.09 | (0.91-1.30) |
p = 0.143 | p = 0.669 | ||||||||||
DI quintile | people with + FOBT | no. of lesions (premal. + malignant) | PPV | OR | (95 % CI) | DI quintile | people with + FOBT | no. of lesions (premal. + malignant) | PPV | OR | (95 % CI) |
I (least disadvantaged) | 773 | 255 | 32.97 | 1.00 | I (least disadvantaged) | 1168 | 594 | 50.18 | 1.00 | ||
II | 789 | 246 | 31.05 | 0.92 | (0.74-1.14) | II | 1295 | 705 | 53.25 | 1.16 | (0.99-1.36) |
III | 735 | 258 | 35.26 | 1.10 | (0.89-1.36) | III | 1292 | 703 | 53.49 | 1.16 | (0.99-1.36) |
IV | 688 | 233 | 33.98 | 1.04 | (0.83-1.29) | IV | 1154 | 617 | 52.57 | 1.11 | (0.94-1.31) |
V (most disadvantaged) | 665 | 197 | 29.00 | 0.85 | (0.68-1.07) | V (most disadvantaged) | 1119 | 608 | 53.29 | 1.14 | (0.96-1.34) |
p = 0.197 | p = 0.349 |
OR Age-adjusted odds ratios, CI Confidence interval
DI quintile: Socioeconomic deprivation index quintile proposed by the MEDEA project; p: significance value of the likelihood ratio test for the association between DI and outcome variable; RII: relative index of inequality
aage-standardized rates per 1000 inhabitants (reference population Basque Country 2011)